Hematinics: Iron, Vitamin B12 and Folate — Mechanisms, Treatment and Monitoring

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview and assessment Hematinics are required for normal erythropoiesis, but iron deficiency, cobalamin deficiency and folate deficiency differ in mechanisms and management. Evaluate the underlying cause of anemia rather than prescribing supplements indiscriminately. Complete blood count, ferritin,…

Read Full News

Fibrinolytic and Antifibrinolytic Drugs: 2026 Stroke Treatment, Tranexamic Acid and Safety

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Clinical overview Fibrinolytics accelerate breakdown of fibrin-rich thrombi, whereas antifibrinolytics inhibit plasmin-mediated fibrin dissolution. Their indications are distinct and time-sensitive. The major hazard of fibrinolysis is intracranial or systemic bleeding; antifibrinolytics require selection based on bleeding etiology…

Read Full News

Antiplatelet Drugs: Aspirin, P2Y12 Inhibitors and 2025 ACS Guidance

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview Antiplatelet drugs inhibit arterial platelet activation and aggregation. They are central to acute coronary syndromes (ACS), post-PCI management and selected secondary stroke prevention, but inappropriate use increases major bleeding. Drug choice and duration are determined by…

Read Full News

Anticoagulants: Heparin, Warfarin, DOACs and Reversal Safety in 2026

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview Anticoagulants prevent or treat fibrin-rich thrombosis, including atrial fibrillation–associated embolism and venous thromboembolism. They do not directly dissolve established clots. Choice considers indication, renal/hepatic function, pregnancy, mechanical valves, bleeding risk and drug interactions [1, 2]. Classes…

Read Full News

Lipid-Lowering Drugs: 2026 ACC/AHA Guideline, Statins, PCSK9 and Safety

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview Lipid-lowering medicines reduce atherosclerotic cardiovascular disease (ASCVD) risk chiefly by lowering LDL cholesterol and other atherogenic lipoproteins. The 2026 ACC/AHA dyslipidemia guideline replaces the 2018 cholesterol guideline and integrates AHA PREVENT risk equations, lifetime lipoprotein(a) assessment,…

Read Full News

Cardiac Glycosides and Inotropes: Digoxin, Dobutamine, Milrinone and Safety

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Cardiac glycosides and parenteral inotropes increase cardiac contractility through different mechanisms. They are not foundational mortality-reducing treatment for most patients with chronic heart failure with reduced ejection fraction (HFrEF): evidence-based neurohormonal therapies remain essential. Digoxin has selected…

Read Full News

Antiarrhythmic Drugs: Vaughan Williams Classes, AF Guidelines and Proarrhythmia

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Assessing haemodynamic stability Before selecting an antiarrhythmic, establish the rhythm, whether a pulse is present and whether the arrhythmia is causing shock, ischaemic chest discomfort, altered consciousness or acute heart failure. These findings determine whether there is time…

Read Full News

Antihypertensive Drugs: 2025 AHA/ACC Guideline, Mechanisms and Safe Treatment

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Hypertension increases the risk of stroke, myocardial infarction, heart failure, kidney disease and premature death. The 2025 AHA/ACC guideline emphasizes repeated accurate blood pressure assessment, lifestyle interventions and individualized drug treatment. Home readings improve monitoring, but confirmation…

Read Full News

Myocardial Infarction Drugs: 2025 ACS Guideline, Reperfusion and Secondary Prevention

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Myocardial infarction (MI) is a time-critical manifestation of acute coronary syndrome (ACS). ST-elevation myocardial infarction (STEMI) and non-ST-elevation ACS require rapid ECG assessment, troponin testing and appropriate reperfusion/risk stratification. Pharmacotherapy complements—not replaces—urgent percutaneous coronary intervention (PCI) when…

Read Full News

Antianginal Drugs: Nitrates, Beta Blockers, Calcium Blockers and Ranolazine

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Angina is discomfort or an anginal equivalent due to myocardial oxygen supply–demand mismatch. In chronic coronary disease, antianginal drugs reduce symptoms, while separate therapies—lipid lowering, antithrombotics when indicated, smoking cessation and risk-factor control—reduce cardiovascular events. Angina caused…

Read Full News